PENICILLIN G SODIUM - Generic Drug Details

What are the generic sources for penicillin g sodium and what is the scope of patent protection?

Penicillin g sodium is the generic ingredient in one branded drug marketed by Bristol Myers Squibb, Copanos, Pharmacia And Upjohn, Sandoz, and Watson Labs Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for penicillin g sodium. One supplier is listed for this compound.

Summary for PENICILLIN G SODIUM

US Patents:	0
Tradenames:	1
Applicants:	5
NDAs:	5
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	13
Patent Applications:	4,977
What excipients (inactive ingredients) are in PENICILLIN G SODIUM?	PENICILLIN G SODIUM excipients list
DailyMed Link:	PENICILLIN G SODIUM at DailyMed

Recent Clinical Trials for PENICILLIN G SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ain Shams University	PHASE2
Shehab Ahmed Hamad	PHASE3
Cairo University	N/A

See all PENICILLIN G SODIUM clinical trials

Pharmacology for PENICILLIN G SODIUM

Drug Class

Penicillin-class Antibacterial

US Patents and Regulatory Information for PENICILLIN G SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INJECTION	061935-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065068-001	Feb 26, 2001		RX	No	Yes
Watson Labs Inc	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	063014-001	Sep 13, 1988		DISCN	No	No

Market Dynamics and Financial Trajectory for Penicillin G Sodium

Last updated: February 14, 2026

Penicillin G sodium, a staple in antibiotic therapy since its discovery, remains relevant mostly in hospital settings and niche applications. Its market landscape is shaped by regulatory environments, antibiotic resistance, manufacturing costs, and competition from newer antibiotics.

Market Overview

Size and Trends: The global antibiotic market was valued at approximately $46.8 billion in 2022, growing at a compound annual growth rate (CAGR) of 3.6% since 2017. Penicillin G sodium constitutes a minor share, roughly 5%, primarily serving hospital-based injections for severe infections. The prevalence of antibiotic resistance and regulatory restrictions limits broader usage.

Geographical Distribution: North America and Europe account for most of the market sales, driven by well-established healthcare infrastructure, higher antibiotic consumption, and regulatory approvals. Developing regions such as Asia-Pacific are increasing consumption, but access issues and regulatory hurdles constrain growth.

Key Application Areas:

• Treatment of streptococcal infections
• Syphilis management
• Endocarditis therapy
• Penicillin-sensitive bacterial infections

Market Drivers and Constraints

Drivers:

• Clinical effectiveness against specific bacteria
• Established manufacturing processes
• Use in hospitals with strict infection control

Constraints:

• Antibiotic resistance proliferation
• Stringent regulatory policies for injectable antibiotics
• Competition from broad-spectrum antibiotics and newer classes such as cephalosporins and carbapenems
• Manufacturing challenges due to complex fermentation processes and raw material costs

Competitive Landscape

Major companies such as Novartis, Merck, and Sandoz produce penicillin G sodium. Competition is low due to high manufacturing barriers and established market share. Patent protections have long expired, leading to generic prevalence, which suppresses prices.

Pricing and Revenue Trajectory

Pricing: The average wholesale price (AWP) for penicillin G sodium injections ranges from $0.10 to $0.50 per vial (1 million units), depending on dosage and region. Cost reductions have occurred with generics over the last two decades.

Revenue Projection: Given the niche application and growing resistance issues, revenues are expected to decline modestly at a CAGR of approximately 1.2% over the next five years, barring new indications or reformulations. Growth in emerging markets could offset some declines but remains limited due to market access barriers.

Regulatory and Patent Outlook

No active patents protect penicillin G sodium, resulting in a commoditized market. Regulatory agencies like the FDA and EMA require ongoing stability, manufacturing consistency, and post-market surveillance due to the injectable form’s critical use environment.

Financial Considerations

Cost Structure: Manufacturing involves yeast and mold fermentation, extraction, and purification, with raw material costs sensitive to supply chain disruptions.

Investment Outlook:

• Low potential for high returns owing to mature status.
• R&D investments unlikely to focus on penicillin G sodium unless exploring novel formulations or resistance-breaking modifications.
• Strategic interest centers on manufacturing efficiencies and geographic expansion in low-resource settings.

---

Key Takeaways

• Penicillin G sodium retains importance in hospital settings for specific infections.
• Market size is limited, with revenue declines projected due to antibiotic resistance and generics.
• Competitive landscape features a handful of manufacturers with no patent protections.
• Pricing is stable with low margins, and innovation focus is minimal unless resistance issues prompt new formulations.
• Growth opportunities outside mature markets are constrained by regulatory and access issues.

---

FAQs

1. What factors limit the growth of penicillin G sodium?
Antibiotic resistance, dominance of broad-spectrum antibiotics, regulatory restrictions, and high manufacturing costs restrict market expansion.

2. How does antibiotic resistance impact the penicillin G sodium market?
Resistance reduces clinical effectiveness, leading to decreased use and market share, especially in settings where resistant strains are prevalent.

3. Are there ongoing developments in penicillin G sodium formulations?
Research is limited; most innovations focus on alternative antibiotics or addressing resistance rather than reformulating existing penicillin G sodium products.

4. What is the role of generics in the market?
Generics dominate due to the expiration of patents, leading to price competition and limited revenue for manufacturers.

5. What are the prospects for penetration into emerging markets?
Growth prospects exist but are limited by supply chain issues, pricing pressures, and regulatory approval processes.

---

Sources

1. MarketsandMarkets, "Antibiotics Market," 2022.
2. IQVIA, "Global Antibiotics Market Data," 2022.
3. U.S. Food and Drug Administration, "FDA-approved Antibiotics," 2023.
4. World Health Organization, "Antimicrobial Resistance," 2022.